"13" . "Despite recent therapeutic advances B-cell chronic lymphocytic leukemia (B-CLL) still represents an incurable disease with standard therapy. Early results of autologous stem cell transplantation (ASCT) suggested a significant proportion of patients remained disease-free for years, raising the possibility of cure. However, recent studies have shown no evidence of plateau in the disease-free curves indicating incurability of B-CLL with ASCT. Initial results of allogeneic stem cell transplantation (allo-SCT) with myeloablative conditioning were disappointing due to the high transplant-related mortality, but let to long-term remission and possible cure in a significant proportion of relapsing and refractory patients. The availability of reduced-intensity conditioning (RIC) has resulted in increased use of allo-SCT and decreased early transplant-related mortality. In this setting the majority of anti-leukemia effect results from the graft-versus-leukemia reaction and not from the chemo-or radiotherapy. I"@en . "B-cell chronic lymphocytic leukemia. Part V. Stem cell transplantation"@en . "B-cell chronic lymphocytic leukemi; allogeneic; autologous; stem cell transplantation"@en . . . "4"^^ . "Transfuze a hematologie dnes" . . "4"^^ . "Navzdory sou\u010Dasn\u00FDm l\u00E9\u010Debn\u00FDm pokrok\u016Fm chronick\u00E1 B-lymfocyt\u00E1rn\u00ED leukemie (B-CLL) p\u0159edstavuje onemocn\u011Bn\u00ED dodnes nevyl\u00E9\u010Diteln\u00E9 standardn\u00ED terapi\u00ED. Prvn\u00ED v\u00FDsledky autologn\u00EDch transplantac\u00ED krvetvorn\u00FDch kmenov\u00FDch bun\u011Bk ukazovaly, \u017Ee zna\u010Dn\u00E1 \u010D\u00E1st pacient\u016F z\u016Fst\u00E1v\u00E1 roky bez zn\u00E1mek choroby, co\u017E vyvol\u00E1valo nad\u011Bji na jejich mo\u017En\u00E9 vyl\u00E9\u010Den\u00ED. Dlouhodob\u00E9 sledov\u00E1n\u00ED v\u0161ak tento optimismus nepotvrdilo, kdy\u017E prok\u00E1zalo postupn\u00FD a systematick\u00FD pokles k\u0159ivek p\u0159e\u017Eit\u00ED bez zn\u00E1mek relapsu choroby. Prvn\u00ED v\u00FDsledky alogenn\u00EDch transplantac\u00ED krvetvorn\u00FDch kmenov\u00FDch bun\u011Bk s myeloablativn\u00EDm p\u0159\u00EDpravn\u00FDm re\u017Eimem nebyly \u00FAsp\u011B\u0161n\u00E9, a to p\u0159edev\u0161\u00EDm d\u00EDky vysok\u00E9 potransplanta\u010Dn\u00ED \u00FAmrtnosti. Navzdory tomu bylo prok\u00E1z\u00E1no, \u017Ee u \u0159ady relabuj\u00EDc\u00EDch a chemorefraktern\u00EDch nemocn\u00FDch m\u016F\u017Ee tento postup navodit dlouhodobou remisi a dokonce je vyl\u00E9\u010Dit. Praktick\u00E9 pou\u017Eit\u00ED alogenn\u00EDch trnasplantac\u00ED s redukovanou intenzitou p\u0159\u00EDpravn\u00E9ho re\u017Eimu (RIC) sn\u00ED\u017Eilo \u010Dasnou transplanta\u010Dn\u00ED mortalitu. Tento l\u00E9\u010Debn\u00FD p\u0159\u00EDstup vych\u00E1z\u00ED z pozn\u00E1n\u00ED, \u017Ee hlavn\u00EDm antileukemick\u00FDm faktorem alo"@cs . . "Chronick\u00E1 B-lymfocyt\u00E1rn\u00ED leukemie. \u010C\u00E1st V. Transplantace krvetvorn\u00FDch bun\u011Bk" . "RIV/61989592:15110/07:00004375!RIV08-MSM-15110___" . "Faber, Edgar" . "RIV/61989592:15110/07:00004375" . "Indr\u00E1k, Karel" . . . "Chronick\u00E1 B-lymfocyt\u00E1rn\u00ED leukemie. \u010C\u00E1st V. Transplantace krvetvorn\u00FDch bun\u011Bk"@cs . "Chronick\u00E1 B-lymfocyt\u00E1rn\u00ED leukemie. \u010C\u00E1st V. Transplantace krvetvorn\u00FDch bun\u011Bk"@cs . "Chronick\u00E1 B-lymfocyt\u00E1rn\u00ED leukemie. \u010C\u00E1st V. Transplantace krvetvorn\u00FDch bun\u011Bk" . "Papaj\u00EDk, Tom\u00E1\u0161" . . . "B-cell chronic lymphocytic leukemia. Part V. Stem cell transplantation"@en . "15110" . . . . "6"^^ . . "Navzdory sou\u010Dasn\u00FDm l\u00E9\u010Debn\u00FDm pokrok\u016Fm chronick\u00E1 B-lymfocyt\u00E1rn\u00ED leukemie (B-CLL) p\u0159edstavuje onemocn\u011Bn\u00ED dodnes nevyl\u00E9\u010Diteln\u00E9 standardn\u00ED terapi\u00ED. Prvn\u00ED v\u00FDsledky autologn\u00EDch transplantac\u00ED krvetvorn\u00FDch kmenov\u00FDch bun\u011Bk ukazovaly, \u017Ee zna\u010Dn\u00E1 \u010D\u00E1st pacient\u016F z\u016Fst\u00E1v\u00E1 roky bez zn\u00E1mek choroby, co\u017E vyvol\u00E1valo nad\u011Bji na jejich mo\u017En\u00E9 vyl\u00E9\u010Den\u00ED. Dlouhodob\u00E9 sledov\u00E1n\u00ED v\u0161ak tento optimismus nepotvrdilo, kdy\u017E prok\u00E1zalo postupn\u00FD a systematick\u00FD pokles k\u0159ivek p\u0159e\u017Eit\u00ED bez zn\u00E1mek relapsu choroby. Prvn\u00ED v\u00FDsledky alogenn\u00EDch transplantac\u00ED krvetvorn\u00FDch kmenov\u00FDch bun\u011Bk s myeloablativn\u00EDm p\u0159\u00EDpravn\u00FDm re\u017Eimem nebyly \u00FAsp\u011B\u0161n\u00E9, a to p\u0159edev\u0161\u00EDm d\u00EDky vysok\u00E9 potransplanta\u010Dn\u00ED \u00FAmrtnosti. Navzdory tomu bylo prok\u00E1z\u00E1no, \u017Ee u \u0159ady relabuj\u00EDc\u00EDch a chemorefraktern\u00EDch nemocn\u00FDch m\u016F\u017Ee tento postup navodit dlouhodobou remisi a dokonce je vyl\u00E9\u010Dit. Praktick\u00E9 pou\u017Eit\u00ED alogenn\u00EDch trnasplantac\u00ED s redukovanou intenzitou p\u0159\u00EDpravn\u00E9ho re\u017Eimu (RIC) sn\u00ED\u017Eilo \u010Dasnou transplanta\u010Dn\u00ED mortalitu. Tento l\u00E9\u010Debn\u00FD p\u0159\u00EDstup vych\u00E1z\u00ED z pozn\u00E1n\u00ED, \u017Ee hlavn\u00EDm antileukemick\u00FDm faktorem alo" . . "3" . . "Raida, Lud\u011Bk" . "1213-5763" . "100-105" . . "413670" . "Z(MSM6198959205)" . . . "CZ - \u010Cesk\u00E1 republika" . . "[08461831B1E3]" . .